{"id":164261,"date":"2022-12-08T00:13:59","date_gmt":"2022-12-08T05:13:59","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/adma-biologics-announces-pricing-of-public-offering-for-60-million-of-common-stock\/"},"modified":"2024-08-18T11:46:32","modified_gmt":"2024-08-18T15:46:32","slug":"adma-biologics-announces-pricing-of-public-offering-for-60-million-of-common-stock","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/adma-biologics-announces-pricing-of-public-offering-for-60-million-of-common-stock.php","title":{"rendered":"ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock"},"content":{"rendered":"<p><![CDATA[RAMSEY, N.J. and BOCA RATON, Fla., Dec.  07, 2022  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (\u201cADMA\u201d or the \u201cCompany\u201d), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting underwriting discounts and commissions and other estimated offering expenses.]]><\/p>\n<p>Read more:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/12\/07\/2569345\/0\/en\/ADMA-Biologics-Announces-Pricing-of-Public-Offering-for-60-Million-of-Common-Stock.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock\">ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read more: ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/adma-biologics-announces-pricing-of-public-offering-for-60-million-of-common-stock.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-164261","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164261"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=164261"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164261\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=164261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=164261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=164261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}